Research
Hormonal
Effects on gastric emptying appeared additive when BI 1820237 was combined with low-dose liraglutide.
Combining BI 1820237 with liraglutide may enhance effects on gastric emptying, which could be relevant for treatment strategies.
StrongSupportsmedium confidence
Post-dose paracetamol PK suggested that BI 1820237 and low-dose liraglutide exhibited additive effects on gastric emptying.
Why this rating
Based on the randomized phase I study design.
Source
A randomized phase I study of <scp>BI</scp> 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity
Nadine Beetz et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15984
rct · n=74Cited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →